Saladax Signs Licensing Agreement with Janssen for Antipsychotic Drug Testing Patents
Saladax Biomedical, Inc., a diagnostics company providing kits to measure drug blood levels for adherence and medication management, has signed a license agreement with Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement Saladax acquired the worldwide exclusive patent rights for diagnostic tests that determine drug levels in patients undergoing treatment with antipsychotic medications. This intellectual property, along with the existing patents that Saladax already owns, places Saladax in a predominant position in the field of antipsychotic drug testing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180626005084/en/
Patients with mental health disorders struggle with high rates of poor antipsychotic drug adherence. It is estimated that 40-60% of patients do not take their antipsychotic medications as prescribed. One major issue in treating patients with mental health disorders is that psychiatrists have limited means to detect non-adherent patients and are often uncertain whether a lack of treatment response is due to poor adherence or true lack of drug efficacy. The Saladax tests will provide clinicians with rapid, objective results so that timely clinical decisions can be made.
“We are very pleased to have signed this agreement and look forward to making this line of reagents the standard of care in the field of psychiatry,” said Saladax CEO, Salvatore Salamone. “This agreement provides us with IP to extend our existing MyCare™ Psychiatry product line to include six commonly used antipsychotics.” Two of the six tests Saladax has developed have already received clearance for sale in Europe and four more tests are expected to have clearance in Q-3 2018. Saladax also plans on submitting these tests to the FDA beginning in June 2018.
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant with Ben Franklin TechVentures® in Bethlehem, PA. Saladax is a client of the Ben Franklin Technology Partners of Northeastern Pennsylvania . Saladax develops novel blood tests to increase the impact of personalized medicine by bringing chemotherapeutic drug monitoring to oncologists and adherence testing to psychiatrists. Saladax believes that truly personalized medicine can only exist when the right drug is given at the right dose. Our diagnostic reagents and kits are currently distributed worldwide excluding the United States. Saladax is ISO 13485:2003 certified.
About the MyCare ™ Psychiatry Product Line
More than 18 million patients are on antipsychotics worldwide. The failure rate for these medications can be as high as 50%. While there are many factors contributing to this inadequate treatment response, many journals and psychiatrists point to rapid drug level tests as an important tool to reduce treatment failure. The MyCare™ Psychiatry product line includes blood-based tests for the antipsychotic drugs risperidone and paliperidone, which have a CE mark and are currently approved for sale on the European market. These immunoassays are run in clinical chemistry laboratories on routine high-throughput instruments and provide rapid test results to help guide physicians in their decision-making process by providing objective evidence of medication levels within a clinically relevant time. The Saladax MyCare Psychiatry line will eventually include tests for total risperidone, paliperidone, clozapine, olanzapine, quetiapine, and total aripiprazole in major markets around the world.
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
VA-SIGNIA-HILTON22.2.2019 18:02:11 | Pressemeddelelse
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events
CA-AXONICS-MODULATION22.2.2019 17:32:09 | Pressemeddelelse
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans
FANTASTEC22.2.2019 15:32:09 | Pressemeddelelse
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App
TRUSTONIC22.2.2019 14:44:10 | Pressemeddelelse
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection
MUNDIPHARMA22.2.2019 14:32:10 | Pressemeddelelse
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer
NC-LENOVO22.2.2019 14:15:07 | Pressemeddelelse
Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum